P1054 Clinical outcomes for ulcerative colitis patients stopping 5-aminosalicylates starting biologics and/or immunomodulator therapy: A Systematic review and meta-analysis

J R Moon,J E Na,J H Ji,H S Lee,J J Park
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1184
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Although 5-aminosalicylic acid (5-ASA), a crucial agent in the treatment of ulcerative colitis (UC), its role in the context of more advanced therapies, including immunomodulators and/or biologics, is not well defined. We sought to perform a systematic review and meta-analysis to assess the pooled consequences of discontinuing 5-ASA in patients with UC undergoing treatment with immunomodulators or biologics. Methods We searched MEDLINE, EMBASE, and the COCHRANE library to identify articles analyzing clinical outcomes associated with either discontinuing or maintaining 5-ASA in UC patients receiving immunomodulators or biologic treatments. A meta-analysis was performed using a random-effects model to pool estimates and report hazard ratios [HRs] or odds ratios [ORs], following the data format specified in the individual studies. Results A total of 6 studies were identified as eligible for the meta-analysis. In UC patients receiving immunomodulators and/or biologics, stopping 5-ASA was not associated with steroid use (HR 0.86, 95% confidence interval [CI] 0.65-1.14 and OR 0.84, 95% CI 0.47-1.51), UC-related hospitalization (HR 0.92, 95% CI 0.69-1.22), UC-related surgery (HR 0.88, 95% CI 0.65-1.18), one-year clinical (OR 0.93, 95% CI 0.63-1.39) and endoscopic (OR 1.24, 95% CI 0.30-5.08) remission. Conclusion The cessation of 5-ASA in UC patients treated with immunomodulators and/or biological agents is not related to worsening of clinical outcomes. This finding suggests a limited role for 5-ASA in the setting of more advanced therapies
gastroenterology & hepatology
What problem does this paper attempt to address?